Evidence map›Paper›PMID 28863182›Full record

ArticlePloS one2017

Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study.

Giulia Morsica, Sabrina Bagaglio, Vincenzo Spagnuolo, Antonella Castagna, Clelia Di Serio, Andrea Galli, Liviana Della Torre, Andrea Andolina, Alexander Pramov, Caterina Uberti-Foppa

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Review
  3. Observational
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Isolated Anti-HBc: Significance and Management.Journal of clinical medicine · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Giulia MorsicaDivision of Infectious Diseases, IRCCS, Ospedale San Raffaele, Milan, Italy.ORCID http://orcid.org/0000-0003-4891-5376
Sabrina BagaglioDivision of Infectious Diseases, IRCCS, Ospedale San Raffaele, Milan, Italy.
Vincenzo SpagnuoloVita-Salute San Raffaele University, Milan, Italy.
Antonella CastagnaVita-Salute San Raffaele University, Milan, Italy.
Clelia Di SerioVita-Salute San Raffaele University, CUSSB (University Centre for Statistics in the Biomedical Sciences), Milan, Italy.
Andrea GalliDivision of Infectious Diseases, IRCCS, Ospedale San Raffaele, Milan, Italy.
Liviana Della TorreDivision of Infectious Diseases, IRCCS, Ospedale San Raffaele, Milan, Italy.
Andrea AndolinaDivision of Infectious Diseases, IRCCS, Ospedale San Raffaele, Milan, Italy.
Alexander PramovVita-Salute San Raffaele University, CUSSB (University Centre for Statistics in the Biomedical Sciences), Milan, Italy.
Caterina Uberti-FoppaVita-Salute San Raffaele University, Milan, Italy.
IRCCS Ospedale San Raffaele · ITVita-Salute San Raffaele University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimAntibodies against hepatitis B core antigen (anti-HBc) are found in 14-44% of patients with HIV infection, but it is still unclear whether hepatitis B virus (HBV) vaccination should be recommended for HIV-positive subjects with isolated anti-HBc (IAHBc). We examined the rate of anamnestic and primary responses (ARs and PRs) and associated factors in a group of HIV-infected patients with an IAHBc profile.

methodsThis prospective study recruited 25 HIV-positive patients with anti-HBc alone who were vaccinated against HBV infection. Those without an AR (anti-hepatitis B envelope antigen [anti-HBs] levels of <10 U/L) or who were hypo-responsiveness (anti-HBs levels of >10 but <100 U/L) four weeks after the first dose of vaccine underwent a full course of vaccinations. Their clinical and virological data, including the presence of occult hepatitis B infection (OBI), were evaluated in accordance with the vaccination schedule.

resultsSix of the 25 patients (24%) showed an AR, four of whom had anti-HBs levels of <100 U/L. Ten of 19 (52.6%) remaining patients became seroprotected after the third dose. OBI was detected in four of the six patients with an AR, two of the 10 patients with a PR, and none of the nine patients who did not respond. Multivariate analysis showed that an AR was associated with the presence of OBI (P = 0.0162), and a PR was associated with HCV antibody status. (P = 0.0191).

conclusionsOur data suggest that testing for anti-HBc alone may not be a reliable means of assessing protection from HBV infection in HIV-positive patients. OBI-positive patients may benefit from a single vaccine dose. Anti-HCV serostatus may affect PRs.

Indexed as

FemaleHepatitis BHepatitis B AntibodiesHepatitis B Core AntigensHepatitis B Surface AntigensHepatitis B VaccinesHIV InfectionsHIV SeropositivityHumansImmunologic MemoryItalyMaleMiddle AgedMultivariate AnalysisPolymerase Chain ReactionProspective StudiesHepatitis B AntibodiesHepatitis B Core AntigensHepatitis B Surface AntigensHepatitis B Vaccines

Identifiers

PMID28863182
PMCPMC5581175
OpenAlexW2750942295

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.